BR112016006665A2 - substratos de metaloproteinase de matriz e outras porções cliváveis e métodos de utilização dos mesmos - Google Patents

substratos de metaloproteinase de matriz e outras porções cliváveis e métodos de utilização dos mesmos

Info

Publication number
BR112016006665A2
BR112016006665A2 BR112016006665A BR112016006665A BR112016006665A2 BR 112016006665 A2 BR112016006665 A2 BR 112016006665A2 BR 112016006665 A BR112016006665 A BR 112016006665A BR 112016006665 A BR112016006665 A BR 112016006665A BR 112016006665 A2 BR112016006665 A2 BR 112016006665A2
Authority
BR
Brazil
Prior art keywords
methods
matrix metalloproteinase
cleavable
substrate
mmp
Prior art date
Application number
BR112016006665A
Other languages
English (en)
Other versions
BR112016006665A8 (pt
BR112016006665B1 (pt
Inventor
R Hostetter Daniel
Grace FLANDEZ Jeanne
Thy Luu Nguyen Margaret
Vasiljeva Olga
James MOORE Stephen
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of BR112016006665A2 publication Critical patent/BR112016006665A2/pt
Publication of BR112016006665A8 publication Critical patent/BR112016006665A8/pt
Publication of BR112016006665B1 publication Critical patent/BR112016006665B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/95Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo “substratos de metaloproteinase de matriz e outras porções cliváveis e métodos de utilização dos mesmos” a invenção refere-se, geralmente, aos polipeptídeos que incluem uma porção clivável que é um substrato para, pelo menos, uma metaloproteinase de matriz (mmp), aos anticorpos ativáveis e outras moléculas maiores que incluem a porção clivável que é um substrato para, pelo menos, uma protease mmp, e aos métodos para produzir e utilizar estes polipeptídeos que incluem uma porção clivável que é um substrato para, pelo menos, uma protease mmp em uma variedade de indicações terapêuticas, diagnósticas e profiláticas.
BR112016006665-0A 2013-09-25 2014-09-25 Polipeptídeo isolado que compreende uma região clivável (cm) que é um substrato de metaloproteinase de matriz, uso terapêutico do mesmo e método para detectar a presença ou ausência de um agente de clivagem e um alvo de interesse em uma amostra BR112016006665B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361882377P 2013-09-25 2013-09-25
US61/882,377 2013-09-25
US201461971332P 2014-03-27 2014-03-27
US61/971,332 2014-03-27
PCT/US2014/057523 WO2015048329A2 (en) 2013-09-25 2014-09-25 Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof

Publications (3)

Publication Number Publication Date
BR112016006665A2 true BR112016006665A2 (pt) 2017-09-12
BR112016006665A8 BR112016006665A8 (pt) 2018-01-30
BR112016006665B1 BR112016006665B1 (pt) 2023-05-30

Family

ID=

Also Published As

Publication number Publication date
EP3049111A2 (en) 2016-08-03
WO2015048329A2 (en) 2015-04-02
JP2023159099A (ja) 2023-10-31
AU2014324884A1 (en) 2016-04-21
JP2016538240A (ja) 2016-12-08
IL244744B (en) 2022-04-01
JP2020015749A (ja) 2020-01-30
AU2023254931A1 (en) 2023-11-16
MX2016003957A (es) 2017-02-02
CN106163556B (zh) 2024-04-09
CN106163556A (zh) 2016-11-23
IL291329A (en) 2022-05-01
AU2014324884B2 (en) 2020-03-26
AU2020203910B2 (en) 2023-10-05
BR112016006665A8 (pt) 2018-01-30
KR102488220B1 (ko) 2023-01-12
RU2715232C2 (ru) 2020-02-26
IL244744A0 (en) 2016-04-21
CA2925106C (en) 2023-11-14
KR20230011497A (ko) 2023-01-20
WO2015048329A3 (en) 2015-06-04
NZ756892A (en) 2022-05-27
US20150087810A1 (en) 2015-03-26
JP2021138707A (ja) 2021-09-16
US20240084022A1 (en) 2024-03-14
JP6915987B2 (ja) 2021-08-11
RU2020106752A (ru) 2020-03-11
NZ718283A (en) 2022-05-27
AU2020203910A1 (en) 2020-07-02
CA2925106A1 (en) 2015-04-02
US20190284283A1 (en) 2019-09-19
US20240150478A1 (en) 2024-05-09
CA3214529A1 (en) 2015-04-02
RU2016115542A3 (pt) 2018-11-01
MX2021000416A (es) 2021-03-25
US11814410B2 (en) 2023-11-14
RU2016115542A (ru) 2017-10-30
KR20160074510A (ko) 2016-06-28

Similar Documents

Publication Publication Date Title
MX2021000416A (es) Substratos de metaloproteinasas de matriz y otras porciones escindibles y metodos para usar los mismos.
BR112017015468A2 (pt) substratos cliváveis por serina protease e cliváveis por metaloprotease da matriz e métodos de uso destes
BR112016017649A2 (pt) substratos para matriptase e para ativador do plasminogênio u e outras porções cliváveis e seus métodos de uso
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
BRPI1011516A8 (pt) Aglomerado de pelo menos uma partícula p, processo para a produção de aglomerados, e, uso dos aglomerados.
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112017023862A2 (pt) anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
BR112014027165A2 (pt) antagonistas de st2l e métodos de uso
BR112018076126A2 (pt) compostos heterocíclicos como antibacterianos
BR112016014756A8 (pt) formulação de selante compreendendo fibrinogênio e zimogênios, seu método de fabricação, recipiente e uso
BR112018075939A2 (pt) compostos heterocíclicos como antibacterianos
ECSP13012384A (es) Composición acuosa que contiene bromhexina
BR112015019817A2 (pt) interface de vedação para um compartimento de telecomunicações
BR112015023142A2 (pt) moduladores de p2x7
GB2519017A (en) Next instruction access intent instruction
BR112018007174A2 (pt) instrumento para higiene bucal com saliências condutoras
BR112015030613A2 (pt) terminal portátil e método de interface de usuário em terminal portátil
BR112017019919A2 (pt) sondas ópticas para metaloproteinases de matriz
BR112015032435A2 (pt) método implementado por computador, sistema, produto de programa de computador, método para completar um poço e método para desenvolver um campo de hidrocarboneto
BR112019007309A2 (pt) anticorpos anti-c1s e métodos de uso dos mesmos
BR112015016744A2 (pt) dispositivo e método de atualização de dados de documento eletrônico
BR112016028252A2 (pt) cambota para suporte e consolidação de uma escavação e método para instalação de uma estrutura para suporte e consolidação de uma escavação
BR112013033051A2 (pt) roda dentada com endentação inclinada e segmento para uma roda dentada
BR112013005148A2 (pt) transformador de fases múltiplas com fases acopladas magneticamente
BRPI0704496A (pt) pigmentos de óxido férrico estáveis à oxidação, processo para a fabricação de pigmentos de óxido férrico, uso dos pigmentos de óxido férrico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/09/2014, OBSERVADAS AS CONDICOES LEGAIS